Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1 text.
    Difference
    0.4%
    Check dated 2026-02-11T14:33:08.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about a funding lapse and NIH Clinical Center operations, and updated the page version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:42:45.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Show glossary toggle added to the page. Minor wording/capitalization changes were made to labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision tag updated to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-28T06:24:10.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page version was updated from v3.3.3 to v3.3.4, with Revision: v3.3.4 added and Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:15:29.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Added a Locations section listing study sites in Florida, Maryland, New Jersey, Ohio, and Texas with revision v3.3.3. Removed the separate state-location entries for Florida, Maryland, New Jersey, Ohio, and Texas and the HHS Vulnerability Disclosure link.
    Difference
    0.6%
    Check dated 2025-12-23T22:50:26.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Publications section now indicates entries are automatically filled from PubMed and may not all pertain to the study, and the revision version was updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:35:32.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.